19 April 2017 2 Min Read
PRICING STRATEGY
Aspen shares take knock
The pharmaceuticals group shares suffer after reports detailing its aggressive pricing strategy for off-patent cancer drugs
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In